<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous experimental studies have shown that <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> (AG) is beneficial in the late phase of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, it has been reported that AG reduces <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> in traumatic brain injury </plain></SENT>
<SENT sid="2" pm="."><plain>However, the effects of AG on post-ischemic <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> and blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability are not clear </plain></SENT>
<SENT sid="3" pm="."><plain>Under chloral <z:chebi fb="1" ids="35505">hydrate</z:chebi> anesthesia, transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced in rats by 60 min of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO), followed by 23 h of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Saline as vehicle or AG at the doses of 75, 150 and 300 mg/kg, i.p., was administered at the beginning or at 1 or 3 h after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequently, 24 h after MCAO <z:hpo ids='HP_0002181'>brain edema</z:hpo>, <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume were evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of AG (150 mg/kg) at the beginning or at 1 or 3 h after MCAO, significantly reduced <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> (P&lt;0.001), while AG at the doses of 75 and 300 mg/kg had no effect </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, treatment with AG (150 mg/kg) significantly reduces Evans Blue extravasation by 48% into ischemic brain compared to the saline group (P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, AG at the doses of 75 and 150 mg/kg significantly reduces cortical and striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (P&lt;0.001), while AG at the dose of 300 mg/kg did not change striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (P&gt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings show that AG significantly reduced post-ischemic increase of <z:hpo ids='HP_0002181'>brain edema</z:hpo> with a 3-h therapeutic window in the transient model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, it seems that at least part of the anti-edematous effects of AG is due to decrease of <z:chebi fb="2" ids="33602">BBB</z:chebi> disruption </plain></SENT>
</text></document>